- |||||||||| letolizumab (BMS-986004) / BMS
Trial completion, Trial completion date, Trial primary completion date: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Aug 14, 2023
P1, N=45, Completed,
Trial completion date: Nov 2022 --> Sep 2023 | Trial primary completion date: Nov 2022 --> Sep 2023 Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Nov 2022 | Trial primary completion date: Sep 2023 --> Nov 2022
- |||||||||| letolizumab (BMS-986004) / BMS
Enrollment closed, Trial completion date, Trial primary completion date: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Jul 27, 2023
P1, N=45, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Nov 2022 | Trial primary completion date: Sep 2023 --> Nov 2022 Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Sep 2024 | Trial primary completion date: Jan 2024 --> Sep 2023
- |||||||||| letolizumab (BMS-986004) / BMS
Phase classification: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Mar 15, 2022
P1, N=36, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Sep 2024 | Trial primary completion date: Jan 2024 --> Sep 2023 Phase classification: P1/2 --> P1
- |||||||||| letolizumab (BMS-986004) / BMS
CD40 Ligand Blockade Prevents Acute Gvhd: Results from a Multicenter Phase I-Ib Trial (Salt Palace Convention Center Hall A) - Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_1142;
P1
Included subjects received 8/8 HLA matched unrelated donor peripheral blood stem cell HCT, and sirolimus/tacrolimus GVHD prophylaxis...TMA was uncommon (n=1), and hepatic VOD/SOS cases (n=4) occurred in the setting of myeloablative busulfan/fludarabine conditioning...Addition of BMS-986004 to standard prophylaxis is safe, and has activity in prevention of GVHD. Additional planned analyses will examine late post-HCT outcomes and interrogate biologic effect of the intervention.
- |||||||||| letolizumab (BMS-986004) / BMS
Enrollment open, Trial initiation date, Trial primary completion date: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Jan 28, 2019
P1/2, N=45, Recruiting,
Additional planned analyses will examine late post-HCT outcomes and interrogate biologic effect of the intervention. Not yet recruiting --> Recruiting | Initiation date: May 2019 --> Jan 2019 | Trial primary completion date: Dec 2022 --> Jan 2024
- |||||||||| letolizumab (BMS-986004) / BMS
Trial initiation date: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease (clinicaltrials.gov) - Nov 21, 2018
P1/2, N=45, Not yet recruiting,
Not yet recruiting --> Recruiting | Initiation date: May 2019 --> Jan 2019 | Trial primary completion date: Dec 2022 --> Jan 2024 Initiation date: Oct 2018 --> Feb 2019
- |||||||||| letolizumab (BMS-986004) / BMS
Trial completion, Trial completion date: Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (clinicaltrials.gov) - Feb 27, 2018
P1/2, N=52, Completed,
Trial primary completion date: Apr 2017 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Feb 2018
- |||||||||| letolizumab (BMS-986004) / BMS
Enrollment closed, Enrollment change: Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (clinicaltrials.gov) - Jun 5, 2017
P1/2, N=52, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Feb 2018 Recruiting --> Active, not recruiting | N=40 --> 52
|
